Absci Corporation

NasdaqGS ABSI

Absci Corporation Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 7.21 M

Absci Corporation Total Non-Current Liabilities is USD 7.21 M for the quarter ending September 30, 2024, a -39.71% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Absci Corporation Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 11.96 M, a -27.18% change year over year.
Absci Corporation Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 16.42 M, a -46.80% change year over year.
Absci Corporation Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 30.86 M.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqGS: ABSI

Absci Corporation

CEO	Mr. Sean McClain
IPO Date	July 22, 2021
Location	United States
Headquarters	18105 SE Mill Plain Boulevard
Employees	155
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Fintech

Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Key trends

Past 5 years